

DOI: 10.1017/cjn.2024.303

This is a manuscript accepted for publication in *Canadian Journal of Neurological Sciences*.

This version may be subject to change during the production process.

1 **DOC screen completion time reflects executive function, speed of processing and fluency**

2

3 Sajeevan Sujanthan, HBSc^{1*}, Alisia Southwell, MPH^{1*}, Tera Armel, HBSc¹, Elaine Xing,
4 HBSc¹, Arunima Kapoor, MSc¹, Xiao Yu Eileen Liu, MSc¹, Krista L. Lanctot, PhD^{2,3,4}, Nathan
5 Herrmann, MD^{2,3,4}, Brian J. Murray, MD^{1,2,3}, Kevin E. Thorpe, MMath^{4,5}, Megan L. Cayley,
6 BScN¹, Michelle N. Sicard, MSW¹, Karen Lien, MD¹, Demetrios J. Sahlas, MD, MSc^{6,7,8},
7 Richard H. Swartz, MD, PhD^{1,3,4,9}

8

9 ¹Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, Toronto

10 ²Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto

11 ³Hurvitz Brain Sciences Research Program, Toronto

12 ⁴University of Toronto, Toronto

13 ⁵St Michael's Hospital, Applied Health Research Centre of the Li Sha Shing Knowledge
14 Institute, Toronto

15 ⁶McMaster University, Hamilton

16 ⁷Department of Medicine (Neurology), Hamilton Health Sciences Centre, Hamilton

17 ⁸Hamilton General Hospital, Toronto

18 ⁹Heart and Stroke Foundation Canadian Partnership for Stroke Recovery

19

20 *The first two authors contributed equally to this work

21

22 **Corresponding Author:** Dr. Richard H. Swartz, Sunnybrook Health Sciences Centre, 2075
23 Bayview Avenue, Toronto, ON, Canada, M4N 3M5, Phone: 416-480-4866 e-mail:
24 rick.swartz@sunnybrook.ca Fax: 416-480-4552

25

26 **Short Title:** DOC screen time as a measure of executive function

27 **Email Address:**

28 Sajeevan Sujanthan – sajeevan.sujanthan@mail.utoronto.ca
29 Alisia Southwell – alisia.bonnick@mail.utoronto.ca
30 Tera Armel – 15ta20@queensu.ca
31 Elaine Xing - elaine.xing@mail.utoronto.ca
32 Arunima Kapoor - aru.kapoor@gmail.com
33 Xiao Yu Eileen Liu - Eileen_148@hotmail.com
34 Krista L. Lanctot - krista.lanctot@sunnybrook.ca
35 Nathan Herrmann - Nathan.Herrmann@sunnybrook.ca
36 Brian J. Murray - brian.murray@sunnybrook.ca
37 Kevin E. Thorpe - kevin.thorpe@utoronto.ca
38 Megan L. Cayley - megan.cayley@uhn.ca
39 Michelle N. Sicard - michelle@tuesdayafternoon.net
40 Karen Lien - karenlien90@hotmail.com
41 Demetrios Sahlas - sahlas@mcmaster.ca
42 Richard H. Swartz - rick.swartz@sunnybrook.ca
43 Keywords: Stroke, cognition, depression, sleep apnea, executive function

44

45 **Authorship:**

46 **SS** – Formal analysis, writing – original draft, writing – reviewing and editing
47 **AS** – Data collection, formal analysis, writing – original draft
48 **TA** – Formal analysis, writing – original draft
49 **EX** – Formal analysis, writing – original draft
50 **AK** – Formal analysis, writing – original draft
51 **XL** - Formal analysis, writing – original draft
52 **KLL** - Resources, supervision, writing – review and editing
53 **NH** - Resources, supervision, writing – review and editing
54 **BJM** - Resources, supervision, writing – review and editing
55 **KET** - Resources, supervision, writing – review and editing
56 **MLC** – Data collection, writing – review and editing
57 **MNS** – Data collection, writing – review and editing
58 **KL** – Data collection, writing – review and editing
59 **DS** - Resources, supervision, writing – review and editing
60 **RHS** – Funding, conceptualization, resources, supervision, writing – original draft, writing –
61 reviewing and editing

62 **Abstract**

63 **Background:** The Depression, Obstructive sleep apnea, and Cognitive impairment (DOC)
64 screen assesses three post-stroke comorbidities, but additional information may be gained from
65 the time to complete the screen. Cognitive screening completion time is rarely used as an
66 outcome measure.

67 **Objective:** To assess DOC screen completion time as a predictor of cognitive impairment in
68 stroke/TIA clinics.

69 **Methods:** Consecutive English-speaking stroke prevention clinic patients consented to undergo
70 screening and neuropsychological testing (n=437). DOC screen scores and times were compared
71 to scores on the NINDS-CSC battery using multiple linear regression (controlling for age, sex,
72 education and stroke severity) and receiver operating characteristic (ROC) curve analysis.

73 **Results:** Completion time for the DOC screen was 3.8 ± 1.3 minutes. After accounting for
74 covariates, completion time was a significant predictor of speed of processing ($p=0.002$, 95% CI:
75 -0.016 to -0.004), verbal fluency ($p<0.001$, CI: -0.012 to -0.006) and executive function
76 ($p=0.004$, CI: -0.006 to -0.001), but not memory. Completion time above 5.5 minutes was
77 associated with a high likelihood of impairment on executive and speed of processing tasks
78 (likelihood ratios 3.9-5.2).

79 **Conclusions:** DOC screen completion time is easy to collect in routine care. People needing
80 over 5.5 minutes to be screened likely have deficits in executive functioning and speed of
81 processing - areas commonly impaired, but challenging to screen for, after stroke. DOC screen
82 time provides a simple, feasible approach to assess these under-identified cognitive impairments.

83 **Data Access:** Data is not available to share publicly, as patients did not consent to public data
84 release.

85 Clinical Trials Registration Identifier: NCT02363114

86 Clinical Trials URL: <https://clinicaltrials.gov/ct2/show/NCT02363114>

87 **Introduction**

88 Stroke is the leading cause of neurological disability in adults¹ and survival after stroke is
89 increasing.²⁻⁴ In addition to physical post-stroke deficits,⁵ approximately 30 to 50% of stroke
90 survivors are affected by each of depression, obstructive sleep apnea (OSA), and cognitive
91 impairment (DOC).⁶⁻⁹ These DOC comorbidities are all associated with poorer functional
92 outcomes,¹⁰ and an increased risk of mortality.¹¹

93 The DOC screen was developed as a feasible and valid tool to screen and stratify stroke
94 patients into high, intermediate, and low risk groups for DOC comorbidities to facilitate
95 detection and management in high-volume stroke clinic settings.¹² The screen is efficient, yet
96 designed to maintain the construct validity of a delayed recall task. Eighty-nine percent of
97 patients in stroke prevention clinics are able to complete the tool in <6 minutes (mean=4.2
98 minutes, SD=1.5).¹² In validation studies, the cognitive component of the DOC score is helpful
99 to quickly stratify people into “cognitively normal”, “cognitively impaired” and “need more
100 assessment” groups, compared to more detailed cognitive testing.¹² Although the DOC
101 completion time was originally collected as a way to assess feasibility, practitioners can record
102 this measure when administering the DOC screen in clinical settings. Several studies have
103 reported the average time taken to complete other well-known cognitive screens as feasibility
104 demonstrations, including the Montreal Cognitive Assessment (MoCA; means ranging from 9.5
105 minutes – 11 minutes)^{13,14} and the Mini Mental State Examination (MMSE; means ranging from
106 8 minutes – 13.4 minutes).^{14,15} However, few studies have assessed the utility of using a
107 cognitive screen’s completion time as a metric to evaluate underlying cognitive abilities, such as
108 executive functioning.

109 Executive dysfunction and delays in speed of processing are the most commonly reported
110 cognitive impairments after stroke. The DOC screen specifically examines mood symptoms,
111 cognitive (executive, memory and abstraction) dysfunction and OSA/fatigue – all of which could
112 be associated with cognitive or psychomotor slowing.¹⁶

113 **Aim**

114 Screen completion time is an immediately available metric, requiring no additional effort from
115 either patients or clinicians, that might reflect executive function. The objective of this study was
116 to determine whether completion time for the DOC screen is a reliable reflection of cognitive
117 dysfunction and whether a single completion time cut-point could indicate cognitive impairment.

118 **Methods**

119 All patients were recruited from the DOC feasibility and validity study.¹² This study included
120 English speaking (or English fluent) patients newly referred to stroke prevention clinics between
121 April 23rd, 2012 and April 30th, 2014 (n=1504) who could complete the screen independently
122 (with the administrator, but without third party support). We excluded patients with severe
123 aphasia, severe motor dysfunction (unable to hold a pen and draw a clock) and patients who were
124 not fluent in English. Each eligible participant was administered the DOC screen (**Figure 1**) as a
125 brief screen of depression, obstructive sleep apnea (OSA) and cognitive impairment. All DOC
126 screens were timed from the beginning of the memory registration (first task) until the end of the
127 5-word free recall (final task). Chart abstractions by trained research members captured
128 demographic and clinical data on all participants from patient charts using previously published
129 and validated methods.^{17,18}

130 To reduce sampling bias, all consecutive patients from stroke prevention clinics who
131 completed the DOC screen were asked to complete more detailed neuropsychological
132 assessments, including a cognitive battery and formal mood assessments as outlined in the DOC
133 feasibility study.¹² All patients who completed the detailed assessments provided written informed
134 consent. Only the site PI could access the information that could identify individual participants,
135 all the other authors were given anonymized study ID that was created upon the completion of
136 the informed consent process. A complete list of all mood and cognitive assessments completed
137 as part of the DOC study is reported elsewhere.¹² In this analysis, cognition was assessed using
138 the 30-minute neuropsychological battery recommended by the NINDS-CSN.¹⁹ This cognitive
139 battery consists of the: Controlled Oral Word Association Test (phonemic fluency), Animal
140 Naming task (semantic fluency), California Verbal Learning Test (CVLT), Digit Symbol
141 Coding, and Trail Making Tests (TMT-A and TMT-B). All scores were normalized (z-score or
142 scaled score) for age using age-matched norms from each respective test manual. CVLT and
143 Animal Naming were also education-standardized.^{20,21} The study was approved by the
144 Sunnybrook Research Ethics Board (approval number SUN-2312).

145 *Statistical Analysis*

146 Statistical analysis was performed using IBM SPSS Statistics for Windows version 24.
147 Descriptive statistics, including means and standard deviations, were calculated for age, screen
148 completion time, and number of years of education.

149 *Multivariable linear regression analyses of the relationship between time-to-completion*
150 *and NINDS-CSC standardized scores*

151 To assess whether screen time reflects cognitive function, independent linear regression models
152 were used to examine the association between DOC completion time and the scaled or z-scores
153 of all neuropsychological subtests. Data from all participants were used in the regression models.
154 A sensitivity analysis was performed using a complete case approach to assess whether missing
155 variables affected the models. All models controlled for age, education, modified Rankin Score
156 (mRS) and sex. Due to the established relationship between the DOC cognitive sub-scores and
157 detailed cognitive assessments,¹² we also controlled for the DOC-Cognition score in all models.
158 To adjust for multiple (7) linear regressions, Bonferroni correction ($0.05/7 = 0.0071$) was used to
159 define significance at $p < 0.007$ for all analyses.

160 *ROC and logistic regression analyses to identify cutoffs associated with high likelihood*
161 *of cognitive impairments:*

162 To identify whether a single cut point (in seconds) for screen time could be found with high
163 specificity and likelihood ratios for cognitive impairment, receiver operating characteristic
164 (ROC) curves were used. ROC analyses were run for each neuropsychological assessment
165 significantly associated with the DOC screen completion time. A logistic regression with screen
166 time completion (as a continuous variable) and the cognitive impairment classification on the
167 NINDS-CSN assessments was applied to the ROC curves. The classification of cognitive
168 impairment of NINDS-CSN was defined as scores >2.0 standard deviations from expected
169 norms, on 2 or more cognitive tasks. This required participants to have completed all tests in the
170 detailed cognitive battery, thus a complete case approach was used for all ROC analyses. First, a
171 single, specific cut-point (time in seconds) was defined based on the ROC curve output for
172 patients with an overall classification of impaired on the NINDS-CSN battery. The cut-point was
173 pre-specified to have 95% specificity for cognitive impairment. This cut-point was then applied
174 to ROC curves from each individual assessment and evaluated using likelihood ratios (LR).

175 **Results**

176 437 patients completed the cognitive and mood gold standard assessments within a maximum of
177 3 months of screening, with the average time interval of 3 days²² (Supplemental Table 1). 213
178 (48.7%) participants were male, the mean (\pm standard deviation) age was 62.7 ± 15.6 years, and
179 the mean years of education was 15.6 ± 3.9 years (**Table 1**). 387 patients were able to complete

180 all assessments in the battery; 13.7 % of those were classified as impaired based on the NINDS-
181 CSN classification. The DOC screen completion mean was 3.8 ± 1.3 minutes (range: 1.9-9.6
182 minutes).134 (31%) patients had an ischemic stroke, 138 (32%) had a probable/possible TIA,
183 and the remainder (37%) were diagnosed with other conditions (**Table 1**). Non-stroke/TIA
184 diagnoses included patients referred with possible stroke symptoms, but whose further
185 investigations revealed alternative diagnoses, as well as patients without specific stroke/TIA
186 symptoms referred for either vascular risk reduction or assessment of incidental abnormal
187 imaging findings.

188 We performed linear regressions with DOC screen completion time (in seconds) as a
189 predictor for each neuropsychological assessment score (**Table 2**). In all models we controlled
190 for age, sex, years of education, screening score of cognitive function (DOC-Cognition score),
191 and overall function (mRS). All regression models for screen completion time were significant (p
192 $< .001$) (Supplemental Table 2). Additionally, model summaries showed that screen completion
193 time was a significant predictor ($p < 0.005$) of: verbal fluency semantic score (95% Confidence
194 Interval (CI) of Beta-coefficient from linear regression: $-.006$ to $-.001$), verbal fluency phonemic
195 Score (95% CI: $-.018$ to $-.006$), Digit Symbol Coding (95% CI: $-.016$ to $-.004$) and the Trail
196 Making Tests (TMT-A 95% CI: $-.017$ to $-.005$; TMT-B 95% CI: $-.016$ to $-.004$). In all cases,
197 these were negative correlations (i.e., longer completion times correlated with poorer cognitive
198 scores). DOC screen completion time was not a significant predictor of memory performance on
199 the CVLT Short Delay Free Recall ($p=.713$, 95% CI: $-.003$ to $.002$) or the CVLT Long Delay
200 Free Recall ($p=.790$, 95% CI: $-.002$ to $.003$). Results did not differ in the sensitivity models with
201 complete case data (see Table 2 compared to Supplemental Table 3 with complete case data).
202 Neither DOC mood and apnea screening scores, nor SCID-D or polysomnogram scores were
203 associated with DOC screen completion time in any multivariable regression.

204 Using the single cut-off point approach on the overall cognitive impairment ROC curve
205 (Figure 2, Table 3A), the point with 95% specificity for cognitive impairment was 332.5
206 seconds. When this time was applied to ROC models for each individual cognitive task (Table
207 3B), the same cut-point had high specificity on all executive and speed of processing tasks. The
208 area under the curve was greater than 0.7 for all executive and speed of processing tasks.
209 Likelihood ratios for predicting abnormal results on executive and speed of processing tasks
210 ranged from four to six – that is, people taking more than 332.5 seconds to complete the DOC

211 screen were 4-6 times more likely to have severe cognitive impairment on executive and speed
212 of processing tasks than those with faster completion times (see Table 3). Scatterplots
213 demonstrating the predicted probability of impairment on each domain by completion time,
214 derived from the logistic regression analysis can be found in the supplemental material.

215 **Discussion**

216 Several studies²³ have shown that post-stroke cognitive impairments can be separated into
217 independent cognitive factors including language, memory and executive function, with deficits
218 in executive functioning and speed of processing being the most common.²⁴ Screening tests for
219 executive function and speed of processing are limited and rarely used in routine clinical care.
220 These results demonstrate that DOC screen completion time is an independent predictor of
221 executive function (semantic fluency,²⁵ TMT-B²⁶), speed of processing (Digit symbol coding,²⁷
222 TMT-A and B²⁸) and verbal fluency²⁹ after stroke, even after controlling for age, sex, education,
223 DOC-Cognition score and stroke severity. Completion time did not predict CVLT scores, a
224 verbal test primarily affecting verbal memory (learning/registration and recall).³⁰ Verbal fluency,
225 while reflecting language function, is also reflective of executive function.³¹ Moreover, we have
226 demonstrated that a 332.5 second (roughly 5.5 minutes) cut-off has 95% specificity and high
227 likelihood ratios for predicting both overall cognitive and executive function impairment. This
228 can be used as a quick and easily obtainable measure to identify people at risk for impairment on
229 executive and speed of processing tasks. Certainly, other timed tasks, whether pen-and-paper
230 (like Trails) or digital (e.g. Creyos), can be used to assess executive and speed of processing
231 deficits in detail; however, detailed cognitive batteries are too onerous for routine clinical use.
232 Simply timing the DOC screen as it is administered provides additional information, beyond the
233 actual DOC cognitive screening score, that can flag people at high risk of having multi-domain
234 cognitive impairment and executive/speed of processing dysfunction.

235 A few notable neuropsychological measures have used completion time to assess specific
236 cognitive functions. For instance, Trail Making Tests (TMTs) are a set of widely accepted timed
237 neuropsychological measures that provide insight into executive abilities.²⁸ Processing speed is
238 highly associated with performance on TMT Part B (a task reflecting attention and executive
239 functions such as set shifting), and with performance on TMT Part A (which is more closely
240 related to motor speed and attention).^{26,32,33} Similarly, Woods et al. discovered that a patient's
241 question completion time on self-paced questionnaires could be used as a measure of executive

242 functioning.³⁴ Question completion time measures processing and decision-making speeds,
243 providing insight into motivation, effort, and cognitive ability that is not measured by existing
244 tests.³⁴ These studies support the notion that timed measures may be useful as a measure of
245 executive dysfunction in addition to their use as screening instruments. The findings presented in
246 our study correspond well to those reported by Woods et al. Their analysis showed that complex
247 tasks, akin to our DOC-Cognitive tasks, were strongly related to executive function and
248 processing speed. Their neuropsychological tests (including TMT-B and Digit Span) also
249 correlated significantly with self-paced question completion time. Their research process was
250 similar to ours, wherein completion time was compared to existing screens to validate
251 completion time as a metric; both studies suggest that completion time of self-paced complex
252 assessments may be valid markers of executive function.

253 Few studies use completion time of a neuropsychological screening tool as a cognitive
254 marker. Most timed tasks examine processing speed directly (e.g. Trails, Symbol-digit modalities
255 test³⁵) and have been studied in clinical settings, for example for HIV induced cognitive
256 dysfunction^{36,37} and in Multiple Sclerosis.^{38,39} However, these types of tasks are more detailed
257 and time consuming, and while they can be performed in clinic in isolation, they are more often
258 done as part of larger batteries. In contrast, screening tasks like the MoCA or MMSE are not
259 routinely timed when applied in clinical settings. By simply timing the DOC screen, in addition
260 to the information generated by the screen on mood, apnea and cognitive function, the time taken
261 to complete the entire screen is itself an indirect measure that can highlight people at risk for
262 cognitive impairment, especially executive, speed of processing and attentional issues.
263 Moreover, executive function deficits are not often assessed in stroke patients; these deficits are
264 subtle, challenging to test for, and often go unrecognized.²⁴ The NINDS-CSC battery is
265 recommended as a research battery, but it requires a trained administrator, and at least 30
266 minutes per person plus scoring. This is not feasible for routine clinic use. The DOC screen, in
267 contrast, takes less than 5 minutes, can be performed by clinical staff (students, administrative
268 assistances, nurses and physicians) and can help to highlight people at risk for impairments in
269 mood, apnea and cognition.

270 The interpretation of our findings is limited by our sample population. Compared to the total
271 number of patients who were asked to volunteer from the stroke prevention clinic (n=1504),
272 consenting participants (n=437) tended to be slightly younger and with slightly milder

273 neuropsychological deficits (healthy participant bias).¹² However, our sample also included a
274 wide range of patients across the full spectrum of severity. As expected from stroke/TIA clinic
275 samples, 62% had a diagnosis of stroke and/or TIA, and the rest had alternative diagnoses
276 common in stroke prevention clinics (mimics, multiple vascular risk factors, abnormal imaging).
277 This heterogeneity reflects the pragmatic nature of the screening and its broad generalizability to
278 the population of patients referred to stroke prevention clinics. TIA patients are well recognized
279 to share similar long-term risk profiles⁴⁰ and are also at risk for cognitive impairment,⁴¹
280 compared to those with imaging confirmed strokes. While the strongest associations to DOC
281 completion were with tests of executive function, processing speed and verbal fluency, other
282 domains that were less well represented in the NINDS-CSC battery could also impact screen
283 completion time. For example, visuospatial function was not specifically assessed in the NINDS-
284 CSC battery; and while language function could also affect completion time, there was no
285 relationship with score on the California Verbal Learning Task (a verbal memory task). Since
286 many tasks have more than one cognitive construct underlying them (e.g. phonemic and
287 semantic fluency tasks each require language, attention and executive functions), DOC screen
288 time cannot be considered a reflection of only one underlying domain. However, the tasks
289 associated with DOC screen time all share underlying cognitive constructs of attention, executive
290 dysfunction and/or speed of processing. The relationship between DOC completion time and
291 gold standard testing was found across a range of severity from normal function to severely
292 impaired. It should also be noted that there is not a single perfect cut-off score for DOC
293 completion time that indicates executive dysfunction. To facilitate clinical utility, and because
294 this is intended as a screen in high-volume clinics, we chose to explore a cut-off with high
295 specificity so clinicians could be confident there was a high likelihood of true cognitive
296 impairment beyond this time; however, this cut-off will have a low sensitivity and will miss
297 some people with cognitive impairments. Previous work has already established that the DOC-
298 Cognition score can also be a sensitive screen, effectively ruling out cognitive impairment in
299 people who score highly.¹² Finally, it is important to note that although screen completion time
300 may be a useful tool to identify people at risk for executive dysfunction, it is still not equivalent
301 to a detailed neuropsychological assessment.

302 **Conclusion**

303 Clinical cognitive screening tools have not commonly used completion time as a metric. We

304 aimed to determine whether the DOC screen completion time could provide clinically relevant
305 information on patients' cognitive function. DOC screen completion time reflects executive
306 function, speed of processing and verbal fluency. When administering the DOC screen,
307 completion time requires no additional time or patient burden to collect. This convenience is
308 vital in busy stroke prevention clinic settings, where there is minimal time for detailed cognitive
309 assessments. Exploring whether screen time can act as a predictor of future outcomes would
310 provide further support the utility of this measure in clinical settings.

311 **Acknowledgments**

312 We would like to acknowledge the DOC participants who volunteered their time for the study.

313 **Sources of Funding**

314 This study was supported by CIHR (Grant Ref No. 137038) and HSF (Project No. 000392). RHS
315 received salary support for research from an Ontario Clinician Scientist (Phase II) Award from
316 the HSF Canada and from the Department of Medicine (Neurology) at Sunnybrook and
317 University of Toronto. In-kind support for data storage was provided by the Ontario Brain
318 Institute and the Ontario Neurodegenerative Disease Research Initiative (ONDRI).

319 **Disclosures**

320 RHS reports ownership shares in FollowMD Inc., a virtual vascular risk reduction clinic. None
321 of the other authors have any conflicts of interest to disclose.

322 **Data Availability**

323 DOC screening for mood, cognition and apnea was performed in stroke prevention clinics under
324 waiver of consent. Patients provided written consent to undergo detailed cognitive testing and to
325 relate their screening results to the detailed neuropsychological testing. However, public release
326 of data was not part of the patient consent.

327

328 **Non-Standard Abbreviations and Acronyms**

329 CVLT – California Verbal Learning Test

330 DOC – Depression, Obstructive Sleep Apnea, Cognitive Impairment

331 MMSE – Mini Mental State Examination

332 MoCA – Montreal Cognitive Assessment

333 OSA – Obstructive Sleep Apnea

334 QCT – Question Completion Time

335 TMT – Trail Making Test

336 **References**

- 337 1. Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological
338 disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
339 *Lancet Neurol.* 2019;18(5):459-480. doi:10.1016/S1474-4422(18)30499-X
- 340 2. Lakshminarayan K, Berger AK, Fuller CC, et al. Trends in 10-Year Survival of Patients With
341 Stroke Hospitalized Between 1980 and 2000. *Stroke.* 2014;45(9):2575-2581.
342 doi:10.1161/STROKEAHA.114.005512
- 343 3. Rodríguez-Castro E, López-Dequít I, Santamaría-Cadavid M, et al. Trends in stroke outcomes
344 in the last ten years in a European tertiary hospital. *BMC Neurol.* 2018;18(1):164.
345 doi:10.1186/s12883-018-1164-7
- 346 4. Waziry R, Heshmatollah A, Bos D, et al. Time Trends in Survival Following First
347 Hemorrhagic or Ischemic Stroke Between 1991 and 2015 in the Rotterdam Study. *Stroke.*
348 2020;51(3):824-829. doi:10.1161/STROKEAHA.119.027198
- 349 5. Verstraeten S, Mark R, Sitskoorn M. Motor and Cognitive Impairment after Stroke: A
350 Common Bond or a Simultaneous Deficit? *Stroke Research & Therapy.* 2016;1(1).
- 351 6. Herrmann N, Seitz D, Fischer H, et al. Detection and treatment of post stroke depression:
352 results from the registry of the Canadian stroke network. *Int J Geriatr Psychiatry.* Published
353 online 2011:n/a-n/a. doi:10.1002/gps.2663
- 354 7. Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-
355 analysis. *J Clin Sleep Med.* 2010;6(2):131-137.
- 356 8. Patel MD, Coshall C, Rudd AG, Wolfe CDA. Cognitive Impairment after Stroke: Clinical
357 Determinants and Its Associations with Long-Term Stroke Outcomes. *J Am Geriatr Soc.*
358 2002;50(4):700-706. doi:10.1046/j.1532-5415.2002.50165.x
- 359 9. Kapoor A, Lanctôt KL, Bayley M, et al. “Good Outcome” Isn’t Good Enough. *Stroke.*
360 2017;48(6):1688-1690. doi:10.1161/strokeaha.117.016728
- 361 10. Kapoor A, Lanctot KL, Bayley M, Herrmann N, Murray BJ, Swartz RH. Screening for Post-
362 Stroke Depression and Cognitive Impairment at Baseline Predicts Long-Term Patient-
363 Centered Outcomes After Stroke. *J Geriatr Psychiatry Neurol.* 2019;32(1):40-48.
364 doi:10.1177/0891988718819859
- 365 11. Swartz RH, Bayley M, Lanctôt KL, et al. Post-stroke depression, obstructive sleep apnea, and
366 cognitive impairment: Rationale for, and barriers to, routine screening. *International Journal*
367 *of Stroke.* 2016;11(5):509-518. doi:10.1177/1747493016641968

- 368 12. Swartz RH, Cayley ML, Lanctôt KL, et al. The “DOC” screen: Feasible and valid screening
369 for depression, Obstructive Sleep Apnea (OSA) and cognitive impairment in stroke prevention
370 clinics. Romigi A, ed. *PLoS One*. 2017;12(4):e0174451. doi:10.1371/journal.pone.0174451
- 371 13. Lees RA, Hendry BA K, Broomfield N, Stott D, Larner AJ, Quinn TJ. Cognitive assessment
372 in stroke: feasibility and test properties using differing approaches to scoring of incomplete
373 items. *Int J Geriatr Psychiatry*. 2017;32(10):1072-1078. doi:10.1002/gps.4568
- 374 14. Barnay JL, Wauquiez G, Bonnin-Koang HY, et al. Feasibility of the cognitive assessment
375 scale for stroke patients (CASP) vs. MMSE and MoCA in aphasic left hemispheric stroke
376 patients. *Ann Phys Rehabil Med*. 2014;57(6-7):422-435. doi:10.1016/J.REHAB.2014.05.010
- 377 15. Molloy DW. *Standardised Mini-Mental State Examination (SMMSE): Guidelines for*
378 *Administration and Scoring Instructions.*; 2014.
- 379 16. Schrijvers D, Hulstijn W, Sabbe BGC. Psychomotor symptoms in depression: A diagnostic,
380 pathophysiological and therapeutic tool. *J Affect Disord*. 2008;109(1-2):1-20.
381 doi:10.1016/j.jad.2007.10.019
- 382 17. Hall R, Khan F, O’Callaghan C, et al. *Ontario Stroke Evaluation Report 2013: Spotlight on*
383 *Secondary Stroke Prevention and Care.*; 2013.
- 384 18. Kapral MK, Fang J, Hill MD, et al. Sex Differences in Stroke Care and Outcomes. *Stroke*.
385 2005;36(4):809-814. doi:10.1161/01.STR.0000157662.09551.e5
- 386 19. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and
387 Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards.
388 *Stroke*. 2006;37(9):2220-2241. doi:10.1161/01.STR.0000237236.88823.47
- 389 20. Tombaugh T. Normative Data Stratified by Age and Education for Two Measures of Verbal
390 Fluency FAS and Animal Naming. *Archives of Clinical Neuropsychology*. 1999;14(2):167-
391 177. doi:10.1016/S0887-6177(97)00095-4
- 392 21. Delis DC, Kramer JH, Kaplan E, Ober BE. *California Verbal Learning Test | Second Edition*.
393 Second. The Psychological Corporation; 2000.
- 394 22. Swartz RH, Cayley ML, Lanctôt KL, et al. The “DOC” screen: Feasible and valid screening
395 for depression, Obstructive Sleep Apnea (OSA) and cognitive impairment in stroke prevention
396 clinics. *PLoS One*. 2017;12(4):e0174451. doi:10.1371/JOURNAL.PONE.0174451
- 397 23. Swartz RH, Stuss DT, Gao F, Black SE. Independent Cognitive Effects of Atrophy and
398 Diffuse Subcortical and Thalamico-Cortical Cerebrovascular Disease in Dementia. *Stroke*.
399 2008;39(3):822-830. doi:10.1161/STROKEAHA.107.491936

- 400 24. Zinn S, Bosworth HB, Hoenig HM, Swartzwelder HS. Executive function deficits in acute
401 stroke. *Arch Phys Med Rehabil.* 2007;88(2):173-180. doi:10.1016/J.APMR.2006.11.015
- 402 25. Maseda A, Lodeiro-Fernández L, Lorenzo-López L, Núñez-Naveira L, Balo A, Millán-Calenti
403 JC. Verbal fluency, naming and verbal comprehension: three aspects of language as predictors
404 of cognitive impairment. *Aging Ment Health.* 2014;18(8):1037-1045.
405 doi:10.1080/13607863.2014.908457
- 406 26. Arbuthnott K, Frank J. Trail Making Test, Part B as a Measure of Executive Control:
407 Validation Using a Set-Switching Paradigm. *J Clin Exp Neuropsychol.* 2000;22(4):518-528.
408 doi:10.1076/1380-3395(200008)22:4;1-0;FT518
- 409 27. Deloire MS, Bonnet MC, Salort E, et al. How to detect cognitive dysfunction at early stages of
410 multiple sclerosis? *Multiple Sclerosis Journal.* 2006;12(4):445-452.
411 doi:10.1191/1352458506ms1289oa
- 412 28. Muir RT, Lam B, Honjo K, et al. Trail Making Test Elucidates Neural Substrates of Specific
413 Poststroke Executive Dysfunctions. *Stroke.* 2015;46(10):2755-2761.
414 doi:10.1161/STROKEAHA.115.009936
- 415 29. Whiteside DM, Kealey T, Semla M, et al. Verbal Fluency: Language or Executive Function
416 Measure? *Appl Neuropsychol Adult.* 2016;23(1):29-34. doi:10.1080/23279095.2015.1004574
- 417 30. JACOBS M, DONDERS J. Criterion validity of the California Verbal Learning Test-Second
418 Edition (CVLT-II) after traumatic brain injury. *Archives of Clinical Neuropsychology.*
419 2007;22(2):143-149. doi:10.1016/j.acn.2006.12.002
- 420 31. Aita SL, Beach JD, Taylor SE, Borgogna NC, Harrell MN, Hill BD. Executive, language, or
421 both? An examination of the construct validity of verbal fluency measures. *Appl Neuropsychol*
422 *Adult.* 2019;26(5):441-451. doi:10.1080/23279095.2018.1439830
- 423 32. MacPherson SE, Cox SR, Dickie DA, et al. Processing speed and the relationship between
424 Trail Making Test-B performance, cortical thinning and white matter microstructure in older
425 adults. *Cortex.* 2017;95:92-103. doi:10.1016/j.cortex.2017.07.021
- 426 33. Fishman KN, Ashbaugh AR, Swartz RH. Goal Setting Improves Cognitive Performance in a
427 Randomized Trial of Chronic Stroke Survivors. *Stroke.* 2021;52(2):458-470.
428 doi:10.1161/STROKEAHA.120.032131
- 429 34. Woods DL, William Yund E, Wyma JM, Ruff R, Herron TJ. Measuring executive function in
430 control subjects and TBI patients with question completion time (QCT). *Front Hum Neurosci.*
431 2015;9(MAY). doi:10.3389/FNHUM.2015.00288

- 432 35. Zaidi KB, Rich JB, Sunderland KM, et al. Methods for Improving Screening for Vascular
433 Cognitive Impairment Using the Montreal Cognitive Assessment. *Can J Neurol Sci.*
434 2020;47(6):756-763. doi:10.1017/CJN.2020.121
- 435 36. Davis HF, Skolasky RL, Selnes OA, Burgess DM, McArthur JC. Assessing HIV-associated
436 dementia: Modified HIV dementia scale versus the grooved pegboard. *AIDS Reader.*
437 2002;12(1):29-31+38.
- 438 37. Van Harten B, Courant MNJ, Scheltens P, Weinstein HC. Validation of the HIV Dementia
439 Scale in an Elderly Cohort of Patients with Subcortical Cognitive Impairment Caused by
440 Subcortical Ischaemic Vascular Disease or a Normal Pressure Hydrocephalus. *Dement Geriatr*
441 *Cogn Disord.* 2004;18(1):109-114. doi:10.1159/000077818
- 442 38. Ezegebe C, Zarghami A, van der Mei I, Alty J, Honan C, Taylor B. Instruments measuring
443 change in cognitive function in multiple sclerosis: A systematic review. *Brain Behav.*
444 2023;13(6):e3009. doi:10.1002/BRB3.3009
- 445 39. Wishart M, Everest MR, Morrow SA, Rose J, Shen L, Feinstein A. Establishing the
446 consistency of a voice recognition symbol digit modalities test analogue. *Mult Scler.*
447 2023;29(13):1676-1679. doi:10.1177/13524585231199321
- 448 40. Edwards JD, Kapral MK, Fang J, Swartz RH. Long-term morbidity and mortality in patients
449 without early complications after stroke or transient ischemic attack. *Can Med Assoc J.*
450 2017;189(29):E954-E961. doi:10.1503/cmaj.161142
- 451 41. Pendlebury ST, Wadling S, Silver LE, Mehta Z, Rothwell PM. Transient Cognitive
452 Impairment in TIA and Minor Stroke. *Stroke.* 2011;42(11):3116-3121.
453 doi:10.1161/STROKEAHA.111.621490
454
455

456 **Figure 1: The Depression, Obstructive sleep apnea (OSA), and Cognitive impairment (DOC)**
 457 screen (freely available for download at www.docscreen.ca).

DOC SCREEN PART 1

Date: _____
 Patient of: _____

Completed by: RN English 1st language Unable to complete due to: Language Resides at: Home Nursing Home / LTC/CCOC HC ESL, fluent Aphasia/Dysphasia Hospital/Resid Facility RA ESL, not fluent Unable to translate Retirement Home Other Residential Facility No Fixed Address UTD

Sex: M F

Education: highest grade (1-12) _____ # of undergraduate years _____ # of graduate years _____

Systolic BP: _____
 Diastolic BP: _____
 Height: _____
 Weight: _____
 Waist/hip circumference: _____ / _____
 Modified Rankin Scale: _____
 0 - No symptoms
 1 - No significant disability despite symptoms, able to carry out all usual duties and activities
 2 - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
 3 - Moderate disability, requiring some help, but able to walk without assistance (with or without cane or walker)
 4 - Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
 5 - Severe disability, bedridden, incontinent and requiring constant nursing care and attention

Clinical Frailty Scale: _____
 1 - Very fit - Robust, active, energetic, well-motivated and fit
 2 - Well - Without active disease - Disease symptoms well controlled
 3 - Well, with treated comorbid disease - Disease symptoms well controlled
 4 - Apparently vulnerable - Not dependent, but common complaints about being 'tired up' or having disease symptoms
 5 - Mildly frail - Limited dependence for ADLs
 6 - Moderately frail - Help required for both IADLs/ADLs
 7 - Severely frail - Completely dependent on others for ADLs, or terminally ill

Please see reverse side!
 Version Date: Mar 13 2014

Please see reverse side!
 Version Date: Mar 13 2014

DOC SCREEN PART 2

★ Time to complete: _____ min _____ s

Memory (Delayed)

Word	FACE	VEGET	CONCRE	DEEP	REC
Word 1					
Word 2					

DOC-Mem1 (Over the last 7 weeks, how often have you been bothered by any of the following problems?)

Item	Not at all	Slightly	Moderately	Very much
Little interest or pleasure in doing things				
Tiredness or exhaustion most of the time				
Feeling slowed down or fatigued				

DOC-Appet

Item	Yes	No
Do you ever lose appetite that eating, food through a tube, or bottle other people?		
Do you often feel weak, fatigued or unable to get up the day after?		
Has anyone observed you lose weight in the last 6 months?		
Do you think of or eat less food than you used to eat?		

Draw a Clock Face (Clock)

Order	1	2
Number		
Hand		

Abstraction: What is the similarity between a g. banana - orange & kate?

A fruit and a colour? A colour and a fruit?

Memory (Delayed Recall)

Word	WITHOUT CLUE	FACE	VEGET	CONCRE	DEEP	REC
Word 1						
Word 2						

B (DOC-Mem1) : /8 **C (DOC-Appet)** : /8 **C (DOC-Cog 1)** : /10

TOTAL DOC SCORE = B + C + (10 - C) = /26

Revised/Revised from: TRILLI, H. et al. An assessment of cognitive impairment in patients with stroke. In: Stroke (2004) 35(12):2107-2111. TRILLI, H. et al. The development of a cognitive impairment screen. In: Stroke (2004) 35(12):2107-2111. TRILLI, H. et al. The development of a cognitive impairment screen. In: Stroke (2004) 35(12):2107-2111. TRILLI, H. et al. The development of a cognitive impairment screen. In: Stroke (2004) 35(12):2107-2111.

458

459

460 **Table 1:** Demographics for participants completing detailed cognitive and neuropsychological
 461 assessments (n = 437).

Variables	Mean (SD)	
Age (years)	62.7 (15.6)	462
Education (years)	15.6 (3.9)	464
DOC screen completion time (s)	227.8 (76.6)	465
Language	n (%)	466
English	363 (83.1)	467
English Second Language	74 (16.9)	468
Sex (female)	51.3%	
Most Responsible Diagnosis		
Undetermined Diagnosis	4 (.9)	
Abnormal CT/MRI Scan	21 (4.8)	
Asymptomatic Carotid Artery Disease	4 (0.9)	
Definite Ischemic Stroke	121 (27.7)	
Definite TIA	54 (12.4)	
Hemorrhage ICH	17 (3.9)	
Hemorrhage IVH	1 (0.2)	
Hemorrhage SAH	4 (0.9)	
Hemorrhage SDH	1 (0.2)	
Other Non-Vascular	96 (22)	
Other Vascular	14 (3.2)	
Possible/Query Ischemic	13 (3.0)	
Possible/Query TIA	84 (19.2)	
Sinovenous Thrombosis	3 (0.7)	
Modified Ranking Scale (mRS)		
0	230 (52.6)	482
1	113 (25.9)	483
2	69(15.8)	484
3	19 (4.3)	485
4	2 (.5)	486
Missing	4 (.9)	487

488 † TIA = transient ischemic attack, ICH = intracerebral hemorrhage, IVH = intraventricular
 489 hemorrhage, SAH = subarachnoid hemorrhage, SDH = subdural hemorrhage, CT = Computed
 490 Tomography, MRI = Magnetic Resonance Imaging
 491 DOC = **D**epression, **O**bstructive sleep apnea (OSA), and **C**ognitive impairment


492 **Table 2:** Linear Regression results showing the effect of the DOC screen completion time on
 493 individual neuropsychological assessments.

Measure	Test	B-value	Sig.	95% Confidence Interval	
				Lower Bound	Upper Bound
Executive Function	Semantic Fluency (Z-score)	-.004	.004	-.006	-.001
Language (verbal fluency)	Phonemic Fluency (Scaled Score)	-.012	< .001	-.018	-.006
Speed of Processing	Digit Symbol Coding (Scaled Score)	-.010	.002	-.016	-.004
Motor & Speed of processing	TMT-A (Scaled Score)	-.011	< .001	-.017	-.005
Executive function & Speed of processing	TMT-B (Scaled Score)	-.010	.002	-.016	-.004
Memory	CVLT Short Delay Free Recall (Z-score)	.000	.713	-.003	.002
	CVLT Long Delay Free Recall (Z-score)	.000	.790	-.002	.003

494
 495 *all models controlled for by age, sex, years of education, DOC-Cognition score and modified
 496 Rankin Scale (mRS)
 497 †significant results bolded and set at $p < 0.007$
 498 † TMT = Trails Making Test, CVLT = California Verbal Learning Test,
 499 DOC = **D**epression, **O**bstructive sleep apnea (OSA), and **C**ognitive impairment

500 **Figure 2** – Receiver Operating Characteristic (ROC) curve, model for overall cognitive
501 impairment with a **cut-off set at 95% specificity**.

502



Area Under the Curve	0.706
Error	0.037
Confidence Interval	.633 - .779

503
504

505 **Table 3** – Receiver Operating Characteristic (ROC) model outputs comparing DOC screen
 506 completion time with full neuropsychological assessments, with a cut off set at **332.5 seconds**
 507 **(95% specificity) obtained from the model for overall cognitive impairment.**
 508

	Cut-off Time (seconds)	Specificity	Sensitivity	Area Under the Curve (AUC)	Likelihood Ratio (LR+)
A) Impairment ROC regression (>2 standard deviations from expected norms on 2 or more tasks)					
Impaired/not	332.5	0.95	0.19	0.706	3.7
B) ROC regressions for each task					
Phonemic fluency	332.5	0.93	0.27	0.735	3.7
Semantic fluency	332.5	0.94	0.30	0.763	4.7
Digit Symbol	332.5	0.92	0.4	0.788	5.1
Trails A	332.5	0.94	0.28	0.737	4.8
Trails B	332.5	0.95	0.30	0.762	5.9

509

510 † Trails = Trails Making Test

511 DOC = **D**epression, **O**bstructive sleep apnea (OSA), and **C**ognitive impairment